Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 2
1992 1
1993 4
1996 1
2001 1
2002 2
2003 2
2004 13
2005 10
2006 10
2007 11
2008 4
2009 9
2010 13
2011 16
2012 21
2013 20
2014 28
2015 44
2016 62
2017 104
2018 151
2019 241
2020 377
2021 463
2022 368
2023 335
2024 110

Text availability

Article attribute

Article type

Publication date

Search Results

2,141 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for portola
Your search for portora retrieved no results
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. Horwitz S, et al. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34921960 Free PMC article. Clinical Trial.
Chronic thromboembolic pulmonary hypertension.
Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP. Kim NH, et al. Eur Respir J. 2019 Jan 24;53(1):1801915. doi: 10.1183/13993003.01915-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545969 Free PMC article. Review.
Factor XI Deficiency.
Lewandowska MD, Connors JM. Lewandowska MD, et al. Hematol Oncol Clin North Am. 2021 Dec;35(6):1157-1169. doi: 10.1016/j.hoc.2021.07.012. Epub 2021 Sep 15. Hematol Oncol Clin North Am. 2021. PMID: 34535287 Free article. Review.
Fibrinogen Supplementation and Its Indications.
Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Grottke O, et al. Semin Thromb Hemost. 2020 Feb;46(1):38-49. doi: 10.1055/s-0039-1696946. Epub 2019 Oct 1. Semin Thromb Hemost. 2020. PMID: 31574543 Free article. Review.
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Connolly SJ, et al. N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7. N Engl J Med. 2019. PMID: 30730782 Free PMC article.
CONCLUSIONS: In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduced anti-factor Xa activity, and 82% of patients had excellent or good hemostatic efficacy at 12 hours, as adjudicated according to prespecif …
CONCLUSIONS: In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduc …
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.
Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, Vanassche T, Verhamme P, Shivakumar S, Gross PL, Lee AYY, Yeo E, Solymoss S, Kassis J, Le Templier G, Kowalski S, Blostein M, Shah V, MacKay E, Wu C, Clark NP, Bates SM, Spencer FA, Arnaoutoglou E, Coppens M, Arnold DM, Caprini JA, Li N, Moffat KA, Syed S, Schulman S. Douketis JD, et al. JAMA Intern Med. 2019 Nov 1;179(11):1469-1478. doi: 10.1001/jamainternmed.2019.2431. JAMA Intern Med. 2019. PMID: 31380891 Free PMC article.
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Siegal DM, et al. N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11. N Engl J Med. 2015. PMID: 26559317 Free article. Clinical Trial.
CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and oth …
CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after ad …
2,141 results